about
Resistant mutations in CML and Ph(+)ALL - role of ponatinib.High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells.Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study.Micellar Enhanced Spectrofluorimetric Method for the Determination of Ponatinib in Human Plasma and Urine via Cremophor RH 40 as Sensing Agent.SCLLTargeting FGFR1 to suppress leukemogenesis in syndromic and de novo AML in murine models.Outcomes of chronic-phase chronic myeloid leukemia beyond first-line therapy.Risks and benefits of phase 1 clinical trial participation.Cardio-oncology Part I: chemotherapy and cardiovascular toxicity.Sufficiency of Single-Arm Studies to Support Registration of Targeted Agents in Molecularly Selected Patients with Cancer: Lessons from the Clinical Development of Crizotinib.Cardiovascular adverse effects of targeted antiangiogenic drugs: mechanisms and management.Faster drug approval: challenges for safety.Clinical Evidence Supporting US Food and Drug Administration Approval of Otolaryngologic Prescription Drug Indications, 2005-2014.Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval.The hazards of rapid approval of new drugs.Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.Cardiovascular risk assessment in oncological clinical trials: is there a role for centralized events adjudication?Identification of ponatinib and other known kinase inhibitors with potent MEKK2 inhibitory activity.A further strategy to combat the high price of anticancer drugs.Peripheral arterial occlusive disease during ponatinib therapy after failure of imatinib: a case report.
P2860
Q27853085-D7AA0D77-4DFB-4219-B912-A0CD20AC5230Q30847302-85B56F1F-7F9A-4078-B1DD-9CD639C767DCQ36087521-182EEF31-FC1C-44BE-99BE-3FB60A3B8389Q36529159-272A15DF-C432-4F6F-93B5-5F059C10BB0DQ37580305-E2350835-4A0F-4626-A8CF-A854F445DEB0Q38216677-D9A871C2-2230-42F4-8AA5-0591642EDCE7Q38222465-4C09F838-D777-494C-9A10-9BD8418F6FE9Q38406251-17FE13BB-2B4B-464B-8A60-9A560FF6BD08Q38721743-6BAE466A-969B-4F8A-9C11-3DAFF143FC76Q38744149-575BEF14-47E9-4D8A-863A-E39AD15BE799Q38866817-3A4B4FB2-BA93-48BC-A87D-DB824DE0A5C6Q39002683-7EC78ACD-0CCE-42B9-B008-A199609C65DAQ39431314-80F9208E-0931-4CAD-B63C-6EE9105E26C3Q39762702-AEF297A5-9BCE-4ECF-9767-9768513A9335Q40063670-C7707B88-71DE-49A3-92E0-8EFC9EC68A91Q41053984-BB33E6F5-059D-47EF-9164-2D69DCAF073AQ41342704-B5BE2472-3DA4-4C4B-A51A-C00C6F4C7DD9Q50599945-FAB038F5-6528-4497-AB23-ADC05319568FQ54389257-D20F5D83-CE26-4A3E-AAD7-0BFBBF99A4BA
P2860
description
article publié dans la revue scientifique Journal of the American Medical Association
@fr
im Januar 2014 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published in The Journal of the American Medical Association
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в січні 2014
@uk
name
The Accelerated Approval of Oncologic Drugs
@en
The Accelerated Approval of Oncologic Drugs
@nl
type
label
The Accelerated Approval of Oncologic Drugs
@en
The Accelerated Approval of Oncologic Drugs
@nl
prefLabel
The Accelerated Approval of Oncologic Drugs
@en
The Accelerated Approval of Oncologic Drugs
@nl
P356
P1476
The Accelerated Approval of Oncologic Drugs
@en
P2093
Sham Mailankody
P356
10.1001/JAMA.2013.284531
P407
P50
P577
2014-01-22T00:00:00Z